UK life sciences investment lags peers as regulators court AI innovation
Britain’s life sciences sector—long anchored by world‑class research, respected regulators and deep scientific talent—is drawing less new investment than key rivals, even as policymakers move to make the UK more attractive to global capital. Data from fDi Markets indicates that in 2024 greenfield foreign direct investment in life sciences was over 385% higher in the United States and more than 38% higher in Germany than in the UK.
The gap has widened over the past decade: both the UK and Germany recorded £0.4 billion of FDI in 2014, yet Germany has materially outpaced the UK since then, creating an approximate 200‑percentage‑point gap in cumulative growth. Regulation remains a double‑edged sword.
The UK’s robust framework is seen as a passport to international markets, but expanding requirements have raised the cost of compliance. In 2025, the Confederation of British Industry reported that 38% of UK companies experienced a material increase in their regulatory burden over the previous five years, with annual compliance costs exceeding £50 million for some larger firms.
Life sciences businesses also face significant patent and other intellectual property expenses; while UK filing costs compare unfavourably with certain Asian jurisdictions, they are broadly aligned with Germany and France. These pressures weigh on capital efficiency, particularly for early‑stage companies.
Regulators have begun to adjust. The MHRA–NICE Aligned Pathway aims to streamline regulatory approval, health technology assessment and NHS reimbursement, with the goal of getting medicines to patients earlier and providing greater certainty for developers and investors.
The MHRA has also made attracting investment an explicit regulatory objective, particularly at the intersection of artificial intelligence and life sciences. It was the first regulator globally to launch a dedicated pilot for AI‑enabled medical devices, allowing developers to test novel technologies within a supervised environment.
In 2026, that work was expanded through the AI Airlock programme, supported by a £3.6 million funding commitment over three years—signalling the regulator’s intention not only to keep pace with technological change but to position the UK as a world‑leading jurisdiction for AI‑driven medical innovation.
The combination of regulatory openness, supervisory credibility and public funding offers a more differentiated proposition than compliance reform alone. Beyond regulation, broader policy dynamics have influenced sentiment.
Periods of political instability and fluctuating confidence in successive governments have weighed on the sector, while comparatively high taxes and less business‑friendly decisions have further constrained investor appetite. Research from the British Property Federation suggests that more than 100 laboratories and R&D facilities could collectively face an annual £50 million increase in business rates in 2026, adding to operating costs.
For now, the UK is trying to strike a balance between safety, speed and commercial viability. Recent reforms point to a shift in approach, but questions remain about the level of investment flowing into the sector and the persistence of relatively weak growth against global peers.